Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 23 |
| Active Pipeline (Recruiting Now) | 9 (3) |
| Completed vs Stopped Early | 13 / 0 (0.0%) |
| Median Closed Actual Enrollment | 371 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Peking University First Hospital | Beijing, Beijing Municipality | 3 |
| West China Hospital of Sichuan University | Chengdu, Sichuan | 2 |
| Peking University Third Hospital | Beijing, Beijing Municipality | 2 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06500689 | To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil | Phase III | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the Shenzhen Salubris Pharmaceuticals Co Interactive Dossier, benchmark peers in Cardiovascular and Thrombosis, or review the Healthcare Price & Patent Cliff Crosswalk.